Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRC-HIVDNA006-00-VP is a multiclade HIV-1 DNA plasmid vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is composed of six DNA plasmids encoding HIV-1 proteins from multiple clades: three plasmids encode Env proteins from clades A, B, and C, and three plasmids encode Gag, Pol, and Nef proteins. When administered, the DNA plasmids enter host cells and express these viral antigens, which are then presented to the immune system to stimulate both cellular (T-cell) and humoral (B-cell) immunity. It was primarily evaluated in Phase I clinical trials for safety and immunogenicity in healthy, uninfected adults, often administered via a needle-free device (Biojector 2000).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VRC-HIVDNA006-00-VP (National Institute of Allergy and Infectious Diseases).